These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 10433957

  • 21. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
    Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI.
    J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
    Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K.
    Clin Cancer Res; 2003 May; 9(5):1815-9. PubMed ID: 12738739
    [Abstract] [Full Text] [Related]

  • 24. Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry.
    Ehara H, Koji T, Deguchi T, Yoshii A, Nakano M, Nakane PK, Kawada Y.
    Prostate; 1995 Dec; 27(6):304-13. PubMed ID: 7501542
    [Abstract] [Full Text] [Related]

  • 25. Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma.
    Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson CN.
    Clin Cancer Res; 2000 Aug; 6(8):3241-8. PubMed ID: 10955810
    [Abstract] [Full Text] [Related]

  • 26. Identification of the G protein-coupled estrogen receptor (GPER) in human prostate: expression site of the estrogen receptor in the benign and neoplastic gland.
    Rago V, Romeo F, Giordano F, Ferraro A, Carpino A.
    Andrology; 2016 Jan; 4(1):121-7. PubMed ID: 26714890
    [Abstract] [Full Text] [Related]

  • 27. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
    Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA, Jones CD, Krishnan V, Lynch R, Osborne HE, Graff JR.
    Cancer Res; 2003 Sep 15; 63(18):6056-62. PubMed ID: 14522935
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Expression of oestrogen receptor-alpha and oestrogen receptor-beta in prostate cancer.
    Yang GS, Wang Y, Wang P, Chen ZD.
    Chin Med J (Engl); 2007 Sep 20; 120(18):1611-5. PubMed ID: 17908481
    [Abstract] [Full Text] [Related]

  • 30. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
    Carruba G.
    J Cell Biochem; 2007 Nov 01; 102(4):899-911. PubMed ID: 17786930
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer.
    Campbell-Thompson M, Lynch IJ, Bhardwaj B.
    Cancer Res; 2001 Jan 15; 61(2):632-40. PubMed ID: 11212261
    [Abstract] [Full Text] [Related]

  • 33. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
    Wang JC, Bégin LR, Bérubé NG, Chevalier S, Aprikian AG, Gourdeau H, Chevrette M.
    Clin Cancer Res; 2007 Apr 15; 13(8):2354-61. PubMed ID: 17406028
    [Abstract] [Full Text] [Related]

  • 34. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma.
    Altinok G, Powell IJ, Che M, Hormont K, Sarkar FH, Sakr WA, Grignon D, Liao DJ.
    Prostate Cancer Prostatic Dis; 2006 Apr 15; 9(1):77-82. PubMed ID: 16331298
    [Abstract] [Full Text] [Related]

  • 35. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P, Amin MB, Xu HJ, Linden MD.
    Mod Pathol; 1998 Mar 15; 11(3):247-52. PubMed ID: 9521470
    [Abstract] [Full Text] [Related]

  • 36. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer.
    Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M.
    Cancer Res; 2000 Aug 01; 60(15):4245-50. PubMed ID: 10945637
    [Abstract] [Full Text] [Related]

  • 37. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
    Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V.
    Anticancer Res; 2003 Aug 01; 23(5A):3825-35. PubMed ID: 14666684
    [Abstract] [Full Text] [Related]

  • 38. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer.
    Bonkhoff H, Berges R.
    Eur Urol; 2009 Mar 01; 55(3):533-42. PubMed ID: 19013008
    [Abstract] [Full Text] [Related]

  • 39. Fibroblast growth factor, estrogen, and prolactin receptor features in different grades of prostatic adenocarcinoma in elderly men.
    Hetzl AC, Montico F, Lorencini RM, Kido L, Cândido E, Billis A, Ferreira U, Cagnon VH.
    Microsc Res Tech; 2013 Mar 01; 76(3):321-30. PubMed ID: 23362007
    [Abstract] [Full Text] [Related]

  • 40. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
    Iemelynova AA, Grygorenko VM, Cheremuha SV, Romanenko AM.
    Exp Oncol; 2009 Dec 01; 31(4):246-9. PubMed ID: 20010526
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.